Login to Your Account

Oxigene's phase II with Avastin/CA4P combo scores OS in ovarian

By Randy Osborne
Staff Writer

Tuesday, May 24, 2016

With a pivotal phase II/III trial to start "in the next several weeks," Oxigene Inc. CEO William Schwieterman said that the just-published results on CA4P paired with approved cancer therapy Avastin in recurrent ovarian cancer "are potentially huge for the field" of vascular-targeted therapy in solid tumors.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription